Trials / Completed
CompletedNCT00833066
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- BioTech Tools S.A. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | gpASIT+TM | entero-coated capsules containing 25µg of gpASIT+TM |
| BIOLOGICAL | Placebo | placebo entero-coated capsules |
| BIOLOGICAL | gpASIT+TM | entero-coated capsules containing 100µg of gpASIT+TM |
| BIOLOGICAL | gpASIT+TM | entero-coated capsules containing 400µg of gpASIT+TM |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-10-01
- Completion
- 2009-11-01
- First posted
- 2009-01-30
- Last updated
- 2011-11-17
Locations
4 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00833066. Inclusion in this directory is not an endorsement.